RCS - Theracryf PLC - Investor webinar

TheracryfAnnouncement

26/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1307Ca&default-theme=true

RNS Number : 1307C  Theracryf PLC  26 March 2025

RNS REACH: non-regulatory announcement

 

 

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Investor Webinar

 

Alderley Park, UK - 26 March 2025: TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on oncology and neuropsychiatry,
announces that Dr Huw Jones, Chief Executive Officer, and Dr Alastair Smith,
Non-executive Chair, will be hosting an investor webinar on Wednesday, 2
April 2025 at 6.00 pm (BST).

 

The webinar is open to all existing and potential investors and will focus on
the Company's plans to drive its Ox-1 addiction and SFX-01 glioblastoma
programmes, following the fundraise which completed earlier this month.
These funds will enable the Company to take the Orexin-1 antagonist to the key
inflection point of clinical trial readiness, allowing it to unlock potential
commercial opportunities.

 

There will be a Q&A session after the presentation and questions can be
pre-submitted as part of the registration process. You can register for the
event for free at:

https://www.turnerpope.com/register/
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.turnerpope.com%2Fregister%2F&data=05%7C02%7CAndy.Thacker%40TurnerPope.com%7Cb70ead4c470f43a159b608dd13a2681a%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638688310462430630%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=gInM1PlCMvpmR0Yxm2X20M834TUFDdcoRrfbPmN%2FJ74%3D&reserved=0)

 

The webinar will be chaired by experienced news and corporate events
presenter, Katie Pilbeam and hosted by TheraCryf's joint broker, Turner Pope
Investments.

 

A more detailed presentation about Orexin-1, the market opportunity and the
science behind the programme will be held in May.

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

 Dr Huw Jones, CEO                                           enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Turner Pope Investments (Joint Broker)                      +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Cavendish Capital Markets (NOMAD & Joint Broker)            +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

 Vigo Consulting                                             +44 (0)20 7390 0231

Rozi Morris
 theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C%3A/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAXDSAFPSEFA